Tamir Biotechnology (formerly known as Alfacell Corp.) has selected Pharmatech Oncology, Inc. as the CRO to run its upcoming Phase II trial of Ranpirnase (Onconase) in combination with platinum doublet chemotherapy for patients with advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC). Complete patient accrual is expected in 12 months, with multiple centers participating in the trial. Pharmatech Oncology is based out of Denver, CO and has extensive experience conducting onc...